Better Health for All

MEDIOS AG's core business is the supply of specialty pharmaceuticals and individualized medications for complex and chronic conditions such as cancer, HIV, and hemophilia.

This indicates that 95-97% of its product portfolio delivers exceptional health benefits, with the entire business devoted to health improvement. There is no evidence to suggest that the company generates revenue from products with significant negative health outcomes.

Fair Pay & Worker Respect

The company reports that 0% of its employees are covered by collective bargaining agreements or recognized unions, as employees have not established a works council and the company is not bound by collective bargaining agreements.

The unadjusted gender pay gap in 2023 showed women earned 26% less than men on average, which is a widening from 17% less in 2022. The rate of work-related accidents per 100 employees was 4.8% in 2023, an improvement from 6.4% in 2022. The employee satisfaction score from the 2023 survey was 60%. The voluntary employee turnover rate was 23.6% in 2023, an increase from 20.2% in 2022. The company reported no compliance violations or suspected cases of discrimination via its whistleblower system in 2023. The proportion of employees on permanent employment contracts is just under 98%, with 20 fixed-term contracts out of 515 employees in 2023. Employees receive an allowance for statutory or private health and long-term care insurance, and 100% of employees are covered by a health management program.

Kind to Animals

MEDIOS AG's business model as a pharmaceutical supply and service provider means that animal testing can be ruled out, as they produce individually tailored medications from finished medicinal products and are not involved in drug research.

This indicates zero animals are used in any testing protocols. Consequently, the company has no in-house or contracted animal testing operations, nor does it engage in R&D relevant to animal-free substitution. Its operations do not involve animal husbandry, captive operations, sourcing of animal products like eggs, meat, or dairy, or impacting wildlife habitats, rendering many animal welfare KPIs not applicable.

No War, No Weapons

MEDIOS AG, a pharmaceutical company, has no reported revenue from arms or defense contracts, nor does it develop or sell dual-use technology.

There is no evidence of defense business requiring board oversight, or any involvement in military AI or surveillance activities. The company has no assets in conflict-exposed sectors, nor does it have mineral inputs in its products. MEDIOS AG has a Code of Conduct, but specific bans on weapons categories are not detailed. The company aims for zero compliance breaches with its ethical standards, and violations trigger investigations. MEDIOS AG signed the UN Global Compact in 2021 and is committed to its principles, as well as the UN Guiding Principles on Business and Human Rights, with third-party assurance of performance.

Planet-Friendly Business

In 2023, Medios AG's total Scope 1, 2, and 3 greenhouse gas emissions were 38,866.5 tons CO₂e, an increase from 29,607.4 tons CO₂e in 2022.

The company sourced just under 41% of its operational energy from renewables in 2023. For waste, 48.0% was recycled or reused in 2023. In terms of capital expenditure, 16% was taxonomy-eligible in 2023, but none was taxonomy-compliant. The company reported zero environmental compliance violations in 2023. The Medios AG building is DGNB certified, which means at least one building is green certified, but the percentage of all facilities is not provided.

Respect for Cultures & Communities

No specific, quantitative evidence was found in the provided articles for any of the KPIs related to Respect for Cultures & Communities. The articles discuss general sustainability efforts, a non-financial statement,

a supplier code of conduct, and a DEI policy, but they do not provide data on formal partnerships with indigenous or local communities, revenue reinvested in local development, cultural appropriation incidents, cultural impact assessment protocols, local employment ratios, community grievance mechanisms, FPIC participation, community governance inclusion, cultural preservation investment, local procurement share, indigenous supplier engagement, cultural site protection, social license to operate, charitable giving to cultural organizations, community fund allocation, language inclusivity, cultural incident response, or cultural sensitivity training completion.

Safe & Smart Tech

No specific, concrete evidence was found in the provided articles to assess MEDIOS AG against any of the 'Safe & Smart Tech' KPIs. The articles primarily focus on financial performance and general corporate information, lacking details on data protection, cybersecurity, AI ethics, or privacy practices.

Mentions of 'no specific data breach information found' or 'no information on encryption implementation' are not considered evidence for scoring purposes, as per the rules. The mention of 'regular training on compliance issues' and 'Compliance with German Corporate Governance Code (DCGK) with exceptions' are too general and do not explicitly refer to security/privacy training or privacy regulations (like GDPR, CCPA) to be scored against the specific KPIs.